Boehringer Ingelheim

News

Boehringer Ingelheim has started a phase 2 trial of a drug that could offer the first oral drug for geographic atrophy, a major cause of sight loss.

Market Access

At Reuters Pharma Europe, Francesco Di Marco of Boehringer Ingelheim focused on the importance of innovating together.

Patients

At Reuters Pharma USA, editor-in-chief Jonah Comstock caught up with Brian Hilberdink, the new head of US human pharma at Boehringer Ingelheim.

Market Access

Brian Hilberdink, Boehringer Ingelheim's new Head of US Human Pharma, fielded questions on a variety of hot topics from the Reuters Pharma USA stage.

News

Boehringer's cystic fibrosis gene therapy is poised to start clinical testing, hoping to offer a one-shot alternative to costly CFTR modulator drugs.

News

Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third quarter.